debt_leverage_profile
Minimal debt; Biomerica operates near debt-free with cash reserves ~$5-8M, so a 20% rate rise has negligible interest expense impact.
Inferred
Agent_Inference
interest_rate_sensitivity
Very low sensitivity; essentially no floating-rate debt exposure, but higher rates compress small-cap biomedical equity valuations and raise future capital costs.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) China-based manufacturing/raw material sourcing for diagnostics components; 2) Taiwan/Asia Pacific for specialty reagents and assay materials.
Inferred
Agent_Inference
international_expansion_readiness
Top markets include Mexico, Europe, Middle East; MXN and EUR devaluation risk moderate, MXN volatility historically 10-15% annually vs USD.
Inferred
Agent_Inference
geographic_footprint
Operations in US (primary), Mexico, Netherlands; EUR and MXN exposure moderate, representing estimated 30-40% of international revenues combined.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Moderate; specialized antigen and antibody suppliers likely represent concentrated input costs, though no single public vendor confirmed >30% share.
Inferred
Agent_Inference
business_model_type_primary
Minimal cloud dependency; Biomerica is a diagnostics hardware/reagent manufacturer — cloud termination would disrupt back-office, not core product delivery.
Inferred
Agent_Inference
business_model_type_secondary
Medical device and IVD diagnostics manufacturer; physical product sales dominate, limiting cloud infrastructure criticality.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company relies on standard ERP/back-office software, not proprietary API-integrated platforms central to revenue generation.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue derives from sale of physical diagnostic products and kits — clearly commodity/product sales, not investment contracts.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate GDPR/CCPA exposure via European subsidiary (Netherlands); limited consumer data collection reduces CCPA risk, but EU patient-adjacent data requires compliance.
Inferred
Agent_Inference
antitrust_exposure_flag
Very low; Biomerica holds minor market share in IVD diagnostics, faces large competitors (Abbott, Roche), and poses no credible monopolization concern.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (~85-90%); revenues from one-time kit/device sales with limited recurring reagent-pull-through contracts.
Inferred
Agent_Inference
monetization_vector
Product sales of rapid diagnostic test kits and OEM supply agreements; some recurring OEM/private-label supply contracts but majority transactional.
Inferred
Agent_Inference
pricing_architecture
Cost-plus pricing typical in IVD; vulnerable to raw material inflation and competitive price pressure from larger-scale rivals with superior cost structures.
Inferred
Agent_Inference
pricing_power_rating
Weak to moderate; limited brand premium in commodity diagnostics segments, though FDA-cleared proprietary tests provide modest defensibility.
Inferred
Agent_Inference
target_gross_margin_bracket
9.4% Gross Margin (Thin (<20%))
High
SEC-XBRL
churn_vulnerability_index
Low free-rider risk; physical product consumption model requires repurchase, but customer retention depends on distributor relationships and product performance.
Inferred
Agent_Inference
headcount_cost_structure
Largely headcount-linear; manufacturing scale requires proportional labor and quality-control staff, limiting operating leverage at current revenue scale (~$12M).
Inferred
Agent_Inference
marginal_cost_of_growth
High marginal cost relative to revenue; doubling revenue would require near-proportional increases in manufacturing labor, materials, and regulatory headcount.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Biomerica does not operate a franchise network.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, unit economics improve modestly via manufacturing overhead absorption, but CAC through distributors remains high and margin expansion limited.
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; diagnostic kit utility is independent of user base size, making defensibility reliant on regulatory clearances and distributor ties.
Inferred
Agent_Inference
asset_efficiency_ratio
-83.6% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; medical diagnostics have inelastic demand drivers, but Biomerica's elective/GI-focused tests may see volume softness in severe downturns.
Inferred
Agent_Inference
customer_segment_primary
Healthcare distributors, hospitals, and clinical labs — concentration risk elevated if top 2-3 distributors represent disproportionate share of ~$12M revenue.
Inferred
Agent_Inference
customer_segment_secondary
OEM/private-label partners and international government health agencies; loss of a single OEM contract could materially impact annual revenue.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
1.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0000073290
High
SEC-EDGAR
ticker
BMRA
High
SEC-EDGAR